- Advertisement -
InterVenn Biosciences announces the completion of a P10-billion Series C financing from SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management. The fund will largely be allocated for the development and commercialization of Dawn, a blood-based test aimed at helping physicians appropriately match cancer patients to the immuno-oncology therapy with the best possible chance of response. InterVenn, headquartered in California, is led by Filipino founder and chief executive Aldo Carrascoso (right), a graduate of the Ateneo De Manila University and Babson College.